Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10730356 | 0.87 | PLA2G4B (0.60) | PLA2G4BNR1H3CYP4F2CYP4A11PTPN11 | |
| SCHEMBL7413008 | 0.86 | SMN1; SMN2 (0.49) | LTA4HKDM4EALDH1A1GAAHPGD | |
| SCHEMBL25081990 | 0.85 | PLA2G4B (0.68) | PLA2G4BNR1H3CYP4F2CYP4A11KDM4E | |
| SCHEMBL30278815 | 0.85 | PLA2G4B (0.68) | PLA2G4BNR1H3CYP4F2CYP4A11KDM4E | |
| SCHEMBL25081989 | 0.85 | PLA2G4B (0.64) | PLA2G4BNR1H3CYP4F2CYP4A11PTPN11 | |
| SCHEMBL30278807 | 0.85 | PLA2G4B (0.64) | PLA2G4BNR1H3CYP4F2CYP4A11PTPN11 | |
| SCHEMBL4843336 | 0.84 | LOXL2 (0.50) | LTA4HKDM4EALDH1A1GAAHPGD | |
| SCHEMBL8355226 | 0.84 | PLA2G4B (0.57) | PLA2G4BALDH1A1GAAPPARDFFAR1 | |
| SCHEMBL22326323 | 0.84 | PLA2G4B (0.55) | PLA2G4BKDM4EALDH1A1GAAPOLB | |
| SCHEMBL25081988 | 0.84 | PLA2G4B (0.71) | PLA2G4BNR1H3CYP4F2CYP4A11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563741-B2 | CDK inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120165335-A1 | CDK INHIBITORS | CURIS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2010075542-A1 | CDK INHIBITORS | CURIS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009036016-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CDK3, CDKL1, CDKL3 | PLA2G4B 3484/4885NR1H3 1666/4885CYP4F2 3883/4885 |
| US-20120165335-A1 | CDK INHIBITORS | CDK3, CDK6, CDKL1 | PLA2G4B 3696/4885NR1H3 2798/4885CYP4F2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.